Superluminal Medicines is a generative biology and chemistry company led by CEO Cony D’Cruz that combines deep biology and chemistry expertise with machine learning and proprietary big data infrastructure to create drug candidates. Its platform uses a predict-design-test architecture that models protein shapes and designs highly selective compounds to target precise structural changes for therapeutic effect. The discovery engine includes in silico pharmacokinetic and toxicology prediction capabilities to accelerate candidate readiness. The company validates its platform via a proprietary pipeline with initial programs focused on high-value G protein‑coupled receptor (GPCR) targets. Superluminal intends to use the funds to progress its lead program into clinical development and to increase the number of small-molecule drug discovery programs focused on GPCR targets. The company is based in Boston, MA. Superluminal Medicines combines deep biology and chemistry expertise with machine learning and proprietary big data infrastructure to create candidate-ready small-molecule compounds. Its platform uses a predict-design-test architecture to model protein shapes and design highly selective compounds with differentiated target product profiles in just months. The discovery engine includes industry-leading in silico pharmacokinetic and toxicology prediction capabilities. Superluminal's pipeline is initially focused on high-value G protein-coupled receptor (GPCR) targets, a large family of proteins with many undrugged members. The company expects a lead program candidate in the near term and plans to use new funding to advance its small-molecule programs. Superluminal is building a team of biologists, chemists, drug developers, and AI/ML experts and is based in Boston.

Total raised

$153M

Funding rounds

2

Latest round

Series A

Latest activity

Sep 2024